Mounjaro has become one of the most searched-for medicines in the UK, and also one of the most misunderstood. Much of what circulates online treats it as a shortcut or a lifestyle purchase, which is both inaccurate and unhelpful for the people it was designed for. It is a prescription-only medicine, licensed for specific clinical situations, and in the UK it can only be supplied after an assessment by a qualified prescriber.
The active ingredient is tirzepatide, and the way it works differs from the earlier generation of weight management injections. That difference explains both why the trial results have drawn so much attention and why the side effects follow a fairly predictable pattern in the first few weeks.
What follows covers what tirzepatide is, what it does in the body, the criteria a UK prescriber applies, what the main trial reported, and what the first three months realistically involve — including who should not take it at all.
What tirzepatide actually is
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is made by Eli Lilly, sold in the UK under the brand name Mounjaro, and given as a subcutaneous injection once a week. In plain terms, it is a single molecule that acts on two gut hormone pathways rather than one.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones. The gut releases them in response to food, and they help coordinate insulin release, blood glucose control and the signals that tell the brain you have eaten enough. Tirzepatide mimics both.
How the dual action differs from GLP-1-only medicines
The earlier weight management injections available in the UK act on the GLP-1 receptor alone. Tirzepatide adds GIP receptor activity alongside it. The two pathways overlap but are not identical, and activating both appears to produce a stronger effect on appetite regulation and glucose handling than activating GLP-1 by itself.
That is a statement about mechanism, not a claim that one medicine is better or safer for any given person. The right choice depends on medical history, other medicines and tolerance — the judgement a prescriber exists to make.
Appetite, satiety and gastric emptying
Three effects matter most in practice. Appetite falls, so the background drive to eat is quieter and food occupies less mental space. Satiety increases, so fullness arrives sooner during a meal and lasts longer afterwards. And gastric emptying slows, so food leaves the stomach more gradually.
That third effect reinforces fullness, but it also causes much of the early nausea, bloating and constipation people report — and it has one further consequence that is easy to overlook.
The MHRA advises that anyone using oral contraceptives should use an additional barrier method, or switch to a non-oral form of contraception, for four weeks after starting tirzepatide and for four weeks after every dose increase, because delayed gastric emptying can reduce how well an oral pill is absorbed. This is a specific, documented warning and worth raising directly at consultation.
The once-weekly pen and how doses are stepped up
Mounjaro is supplied in the UK as a KwikPen, a pre-filled pen taken once a week on the same day, dispensed in four-week packs at a single strength. Pens need refrigerating at 2–8°C, with a limited period permitted out of the fridge at up to 30°C; the patient information leaflet gives the exact limits.
Dosing is deliberately gradual. Treatment starts at 2.5 mg weekly for four weeks, and that starting dose is not a treatment dose — its purpose is to let the body adjust. Increases of 2.5 mg follow no sooner than every four weeks, guided by tolerance and response.
StageWeekly dosePurposeWeeks 1–42.5 mgStarting dose for tolerance, not a treatment doseFrom week 55 mgFirst maintenance-level doseSubsequent steps7.5 mg, 10 mg, 12.5 mgIncreases of 2.5 mg, no sooner than every 4 weeksMaximum15 mgHighest licensed weekly dose
Reaching 15 mg is not a target. Prescribers frequently hold someone at a lower dose if it is working and well tolerated, and stepping up more slowly is a normal clinical decision rather than a setback. None of the above is a dosing instruction; your own schedule is set by your prescriber.
Who a UK prescriber will consider it for
Private UK pharmacies generally apply a consistent set of criteria: 18 or over, and a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as type 2 diabetes, hypertension or dyslipidaemia. There is normally also an expectation that lifestyle change alone has not been enough.
Those thresholds exist because the medicine was studied and licensed in that population. Someone with a BMI in the healthy range falls outside them, and a responsible service will say so. People searching for where to buy mounjaro in the UK are, in practice, looking for a GPhC-registered pharmacy that will assess them against these criteria first and prescribe only where it is clinically appropriate.
NHS access is narrower
NICE technology appraisal TA1026 recommends tirzepatide for managing overweight and obesity, but NHS England is implementing it in phases. In primary care the initial phase is limited to people with a BMI of 35 or more, adjusted for ethnicity, plus four weight-related conditions drawn from dyslipidaemia, hypertension, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. Specialist weight management services may work to different criteria, NICE will review after three years, and local integrated care boards decide how rollout happens in each area. If NHS access matters to you, ask your GP or ICB where things stand locally.
What SURMOUNT-1 showed, and why an average is not a promise
SURMOUNT-1 ran for 72 weeks in adults with obesity, or overweight with a weight-related condition, who did not have type 2 diabetes. Alongside diet and exercise, it reported mean weight reduction of roughly 15% at 5 mg, around 19.5% at 10 mg and around 21% at 15 mg.
Those are trial averages, and an average describes a group rather than forecasting an individual. Some participants lost considerably more than the mean, some considerably less, and a proportion stopped early because of side effects. Every figure was produced with structured dietary and activity support in place throughout.
Pharmacies publish their own outcome data too. Cured Pharmacy, a UK registered pharmacy that requires an online consultation before any supply, cites an average of about 17% with roughly one in three patients exceeding 20%. Treat any such number as context for a conversation with a prescriber, not as a result you have been promised.
Used alongside diet, activity and review, not instead of them
The medicine reduces appetite; it does not decide what you eat, and it does not build the habits that determine what happens when treatment eventually changes or stops. That is why ongoing review with a prescriber or pharmacist is part of the treatment rather than an optional extra.
Protein intake and resistance activity matter here for a practical reason. When appetite falls sharply, total intake can drop further than intended, and weight lost without attention to muscle is not the outcome most people are after.
What an online consultation involves
A legitimate UK online consultation is a clinical assessment, not a checkout form. Expect questions about height and weight, medical history, current medicines, previous weight management attempts, allergies, pregnancy or breastfeeding status, and any history of pancreatitis, gallbladder disease, thyroid conditions, eating disorders or diabetic retinopathy. Photographic evidence of weight and your GP’s details are usually requested too.
A prescriber reviews all of that and can decline — because BMI falls below the threshold, because of a contraindication or interaction, because answers are inconsistent or incomplete, or because another route would serve you better. A service that never declines anyone is not assessing anyone, which is a warning sign rather than a convenience.
Who it is not suitable for
- Anyone who is pregnant, breastfeeding or planning a pregnancy.
- Anyone with a personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia type 2 (MEN2).
- Anyone under 18.
- Anyone whose BMI falls below the eligibility thresholds described above.
Caution — meaning a careful individual assessment rather than an automatic no — applies to people with a history of pancreatitis, severe gastrointestinal disease or diabetic retinopathy. Anyone taking insulin or a sulfonylurea needs particular care, because the risk of low blood sugar is higher in that combination.
Side effects and what to watch for
The common side effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, reduced appetite and abdominal discomfort. They are typically worst in the first weeks and in the days after each dose increase, and often settle as the body adjusts.
Less common effects include injection-site reactions, fatigue, dizziness and hair thinning. Serious but uncommon problems include pancreatitis, gallbladder problems, and dehydration or kidney injury caused by persistent vomiting. Severe or persistent abdominal pain, particularly pain radiating to the back, and vomiting that stops you keeping fluids down both warrant prompt medical attention. Read the patient information leaflet supplied with your pen, and speak to your GP, pharmacist or prescriber about anything that concerns you.
What the first three months tend to look like
Month one is the adjustment period at 2.5 mg. Appetite usually becomes noticeably quieter within a week or two, and nausea, if it appears, tends to be at its most obvious now. Weight change in this month is often modest, which is expected rather than a sign of failure.
Month two typically brings the first dose increase, and with it a short return of gastrointestinal symptoms for a few days. This is also the point at which the contraceptive advice applies again if it is relevant to you. Many people find a rhythm here: smaller meals and a clearer sense of what portion size now feels comfortable.
By month three a pattern is usually visible — including, for some people, the pattern that this is not the right medicine for them. Side effects may not settle, or the response may not justify continuing. Reviewing honestly with your prescriber at this stage is more useful than persevering in silence.
Buying safely in the UK
The MHRA has repeatedly warned about counterfeit weight-loss pens sold through social media and unregistered websites. Some contain the wrong drug, some nothing active at all. Any seller offering these pens without a consultation is operating outside UK law.
Before using any online pharmacy, check the GPhC register at pharmacyregulation.org.uk for both the pharmacy and its superintendent pharmacist, look for the registered premises number and the distance-selling logo, and confirm that a genuine clinical consultation is required before supply. Prices vary between registered pharmacies and rise with strength; at the time of writing a four-week pack typically ranges from about £145 at 2.5 mg to about £287 at 15 mg.
Common questions
Can I get Mounjaro without a prescription in the UK?
No. Mounjaro is a prescription-only medicine and can only be supplied after an assessment by a qualified prescriber. Any UK source offering it without one is not operating legally.
How long does someone stay on it?
There is no single answer. It is used as an ongoing treatment with regular review, and appetite frequently returns when treatment stops. Duration is a decision to make with your prescriber.
What happens if a weekly dose is missed?
The patient information leaflet sets out what to do, and it depends on how long it has been. Check the leaflet and contact your pharmacist or prescriber rather than doubling up.
Does it work without changing how you eat?
The trial results were all produced alongside dietary and activity support, so they cannot be read as results for the medicine on its own. Reduced appetite makes changes easier to sustain; it does not replace them.
Weighing it up
Tirzepatide is a serious medicine with a documented mechanism, meaningful trial evidence and a real side-effect profile, prescribed against defined clinical criteria. It is not a cosmetic product and not a quick fix. For people who meet those criteria and engage with the dietary, activity and review side of treatment, it is a legitimate option worth discussing.
The most useful next step is a conversation with a clinician who can see your full history — your GP, or a prescriber at a GPhC-registered pharmacy — rather than a decision made from a search results page.
This article is general information and is not medical advice. It is not a substitute for an individual assessment. Speak to your GP, pharmacist or prescriber before starting, changing or stopping any medicine, and always read the patient information leaflet supplied with it.
